PhaseBio Pharmaceuticals. has filed a patent for pharmaceutical formulations that offer sustained release and improved pharmacokinetics for peptide and small molecule drugs. The patent also includes methods for delivering treatment regimens using a combination of sustained release and long half-life formulations. GlobalData’s report on PhaseBio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights PhaseBio Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on PhaseBio Pharmaceuticals, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. PhaseBio Pharmaceuticals's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Sustained release pharmaceutical formulations for improved pharmacokinetics

Source: United States Patent and Trademark Office (USPTO). Credit: PhaseBio Pharmaceuticals Inc

The patent application (Publication Number: US20230414773A1) describes a sustained-release pharmaceutical formulation designed to provide slow absorption of a therapeutic agent from an injection site, characterized by a Tmax of greater than 5 hours. The formulation includes an elastin-like polypeptide (ELP) amino acid sequence with specific characteristics, such as a transition temperature between 26°C and 37°C, and various ratios of amino acids V, G, and A. This formulation aims to offer a flat pharmacokinetic profile compared to the active agent alone, with the ability to form a reversible matrix at body temperature.

Furthermore, the patent application details the use of this pharmaceutical formulation with various therapeutic agents, including proteins, chemotherapeutic agents, and chemical conjugates. The formulation can be administered through pre-dosed pens or syringes at different frequencies, ranging from once per week to multiple times per month. Additionally, the method for delivering this sustained-release regimen involves administering the formulation to a subject in need, with dosing frequencies tailored to the individual's requirements. Overall, the patent application highlights the innovative approach of utilizing ELP amino acid sequences to achieve sustained release and controlled absorption of therapeutic agents, potentially improving treatment outcomes and patient convenience.

To know more about GlobalData’s detailed insights on PhaseBio Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies